Holen Sie sich die Stockscreener-App
1,072.60
0.70%
7.60
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,065.00
Offen:
$1075
24-Stunden-Volumen:
1.84M
Relative Volume:
0.60
Marktkapitalisierung:
$956.66B
Einnahmen:
$72.25B
Nettoeinkommen (Verlust:
$25.28B
KGV:
38.61
EPS:
27.781
Netto-Cashflow:
$10.37B
1W Leistung:
+4.99%
1M Leistung:
+21.32%
6M Leistung:
-2.89%
1J Leistung:
+50.26%
1-Tages-Spanne:
$1,060.36
$1,082.00
1-Wochen-Bereich:
$1,003.69
$1,082.00
52-Wochen-Spanne:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,072.81 | 949.70B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.81 | 564.11B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.61 | 381.10B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.24 | 302.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.28 | 290.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Lilly Goes on $20 Billion Buying Spree as Company Seeks Next Act - Bloomberg.com
LLY: Eli Lilly Acquires Three Vaccine Developers for $3.8 Billio - GuruFocus
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms - Proactive financial news
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve - BioPharma Dive
Lilly goes on $21B buying spree to build drug pipeline - dailyjournal.net
Lilly to buy three vaccine developers for nearly US$4 billion in infectious disease push - CTV News
Lilly spends nearly $4B to acquire three vaccine developers - Indianapolis Business Journal
Eli Lilly and Co. splashes out $3.8 billion to acquire three companies, aiming to get a head start in the next round of the global vaccine race - 富途牛牛
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - upi.com
Analyst recommendations: Eli Lilly, AutoZone, BP plc, Ferrari, Samsung Electronics… - marketscreener.com
Eli Lilly spending up to $3.8 billion to buy vaccine makers - Axios
Positive Clinical Data for Eli Lilly's Gene Editing Therapy VERVE-102 - GuruFocus
Eli Lilly Bets Nearly $4 Billion on Vaccines: Is the Weight-Loss Drug Giant’s Next Growth Curve Here? - TradingKey
Lilly Expands Into Vaccines With Three Infectious Disease Acquisitions Worth Up to $3.8 Billion - citybiz
Lilly to Acquire Vaccine Company in $1.55 Billion Bet on Epstein-Barr Vaccine Development - citybiz
Lilly to Acquire Curevo in Deal Focused on Next-Generation Shingles Vaccine - citybiz
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Here’s What the Street is Saying About Eli Lilly and Company (LLY) - Insider Monkey
Eli Lilly (LLY) Acquires Three Vaccine Firms for Nearly $4 Billi - GuruFocus
Eli Lilly's VERVE-102 Shows Promising Results in Early Trial - GuruFocus
Eli Lilly (LLY) Expands Vaccine Portfolio with $4B in Acquisitio - GuruFocus
Eli Lilly (LLY) Expands Infectious Disease R&D Through New Acqui - GuruFocus
Lilly dives into vaccine research with 3 biotech buyouts - Yahoo Finance
Lilly (LLY) to Acquire LimmaTech Biologics for Up to $780 Millio - GuruFocus
LLY Acquires Vaccine Company Focused on Innovative Nanoparticle Technology - GuruFocus
LLY Expands Vaccine Portfolio with Curevo Acquisition - GuruFocus
Lilly to buy three vaccine developers for up to US$3.8 bil - The Edge Malaysia
Eli Lilly Doubles Down On Vaccines Portfolio; Makes Three Key Acquisitions For Nearly $4 Billion - NDTV Profit
Is LLY Overvalued? DCF Says Worth $762 - GuruFocus
Lilly acquiring three vaccine developers for nearly $4-billion - The Globe and Mail
Lilly announces three acquisitions to build infectious disease portfolio | Eli Lilly and Company - investor.lilly.com
Eli Lilly (LLY) Expands Portfolio with Infectious Disease Acquis - GuruFocus
Lilly to acquire three vaccine developers for up to $3.83 billion - Investing.com
BofA raises Eli Lilly stock price target on GLP-1 growth outlook - Investing.com
Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion - Bloomberg.com
Lilly to acquire three vaccine developers for nearly $4 billion - Reuters
Lilly to acquire three vaccine developers in deals worth up to $4B - Seeking Alpha
Lilly to acquire three vaccine developers for up to $3.83 billion By Investing.com - Investing.com Canada
Eli Lilly to buy three vaccine firms for $4B - Breakingthenews.net
Eli Lilly to Acquire Curevo, LimmaTech Biologics, Vaccine for Up to $3.83 Billion - Moomoo
Eli Lilly Insiders Added US$4.54m Of Stock To Their Holdings - Moomoo
Curevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention - Benzinga
Exclusive | Lilly Agrees to Buy Trio of Vaccine Developers - WSJ
Leerink reiterates Eli Lilly stock rating on gene therapy progress - Investing.com
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Benzinga
Chilton Investment Trims Eli Lilly Stake, Sells 4,088 Shares - The Globe and Mail
Eli Lilly’s one-shot gene therapy shows promise in cutting ‘bad’ cholesterol - Firstpost
Watch Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion - Bloomberg.com
Eli Lilly weight loss drug data supports long-term obesity market position, says UBS - Yahoo Finance UK
Eli Lilly (LLY) Reports Promising Results for Verve-102 in Heart-2 Study - GuruFocus
One-dose gene edit from Eli Lilly kept LDL low for up to 18 months - Stock Titan
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
0.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):